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Abstract Chymase shows a catalytic efficiency in the formation 
of angiotensin (Ang) II. In the present study, the characterization 
and primary structure of monkey chymase were determined, and 
the pathophysiological role of chymase was investigated on the 
atherosclerotic monkey aorta. Monkey chymase was purified 
from cheek pouch vascular tissue using heparin affinity and gel 
filtration columns. The enzyme rapidly converted Ang I to Ang II 
(Km - 98 uM, kcstt - 6203/min) but did not degrade several 
peptide hormones such as Ang II, substance P, vasoactive 
intestinal peptide and bradykinin. The primary structure, which 
was deduced from monkey chymase cDNA, showed a high 
homology to that of human chymase (98%). The mRNA levels of 
the aorta chymase were significantly increased in the athero-
sclerotic aorta of monkeys fed a high-cholesterol diet. These 
results indicate that monkey chymase has a highly specific Ang 
Il-forming activity and may be related to the pathogenesis of 
atherosclerosis. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Angiotensin (Ang) II, a potent pressor substance, is known 
to be generated from Ang I by angiotensin converting enzyme 
(ACE: EC 3. 4. 15. 1) in blood and several tissues. However, 
the Ang Il-forming pathways in human do not always follow 
the classical renin-angiotensin system. Our previous study 
demonstrated that only 30% of the Ang I-induced vasocon-
striction of the isolated human gastroepiploic artery is inhib-
ited by A C E inhibitors and the rest by chymostatin [1]. Hu-
man chymase efficiently generates Ang II [1-3], but some non-
human chymases do not generate Ang I I ; for example, rat 
chymase hydrolyzes the Tyr4-Ile5 bond of Ang I to yield in-
active fragments [4,5], and the chymase-dependent Ang Il-
forming pathway does not exist in rabbit vascular tissues 
[1]. Therefore, human tissues have two Ang Il-forming path-
ways, whereas rats and rabbits have only the A C E pathway. 
The species difference in chymase's Ang Il-forming ability 
should be considered in selecting experimental models for 
studying the pathogenesis of human disease where Ang II is 
involved. 
Recently, it has been emphasized that Ang II play a crucial 
role in the promot ion of vascular tissue remodeling. A C E 
inhibitors suppressed the development of atherosclerosis in 
rabbit [6,7]. These results suggest that the activation of Ang 
II formation in vascular tissues has an important role in the 
pathogenesis of atherosclerosis. However, human vascular tis-
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sues contain Ang Il-forming chymase in addition to ACE, 
and it is not clear whether vascular chymase is related to 
atherosclerosis. 
To establish animal models for exploring the role of the 
chymase-dependent Ang Il-forming pathway in humans, we 
purified and cloned monkey chymase from vascular tissues, 
and investigated the pathophysiological roles of vascular chy-
mase in atherosclerosis. 
2. Materials and methods 
Twelve male monkeys ( ) were obtained from 
Japan SLC (Shizuoka, Japan). In atherosclerotic models, monkeys 
were assigned to normal or high-cholesterol (4% cholesterol and 6% 
corn oil, Oriental Yeast Co. Ltd., Osaka, Japan) diets for 6 months. 
The monkeys were sacrificed by bleeding under pentobarbital anes-
thesia, and their cheek pouch vascular tissues and thoracic aorta were 
excised. The experimental procedures for animals were in accordance 
with the Guide for the Care and Use of Laboratory Animals (Animal 
Research Laboratory, Osaka Medical College). 
The tissue extract was obtained from cheek pouch vascular tissues 
by the procedure described previously [8]. The tissue extract was ap-
plied to a heparin affinity column (5 ml; HiTrap Heparin packed 
column, Pharmacia, Tokyo, Japan) which was pre-equilibrated with 
20 mM Tris-HCl buffer, pH 8.0, containing 0.1 M KC1. The column 
was eluted with a linear gradient (0-100%) of 20 mM Tris-HCl buffer, 
pH 8.0, containing 1.8 M KC1 and 0.1% (v/v) Triton X-100. The 
active fractions with Ang Il-forming activity were applied to a gel 
filtration column (2.6X40 cm; Toyopearl HW-55, Tohsoh, Tokyo, 
Japan) and eluted with 20 mM KC1, pH 8.0, containing 0.5 M KC1 
and 0.1% (v/v) Triton X-100. Ang Il-forming activity was assayed 
according to Okunishi et al. [9]. One unit of chymase activity was 
defined as 1 umol of Ang II formed/minute. The protein concentra-
tion was measured by bicinchoninic acid protein assay reagent (Pierce 
Chemical, Rockford, IL). 
SDS-PAGE was performed on the purified enzyme of 0.5 ug and 
the gel was silver-stained. The optimum pH for Ang II formation was 
determined with Briton-Robinson's wide range buffer of pH 6.0-10.0. 
The susceptibility of the purified enzyme to various inhibitors was 
examined. These inhibitors included ethylenediaminetetraacetic acid 
(EDTA), phosphoramidon, pepstatin, ACE inhibitors (captopril and 
lisinopril), soybean trypsin inhibitor (SBTI), phenylmethylsulfonyl flu-
oride (PMSF), chymostatin, and aprotinin. To determine the substrate 
specificities and the kinetic parameters of the purified enzyme for Ang 
Il-processing, 12 ng of the purified enzyme were incubated in 20 mM 
Tris-HCl buffer, pH 8.0, containing 0.5 M KC1 and 0.1% (v/v) Triton 
X-100 at 37°C. Amino-terminal sequencing of the purified enzyme 
was performed on an Applied Biosystems model 477A protein se-
quencer (Foster City, CA). 
Monkey chymase cDNA was cloned using a polymerase chain re-
action (PCR). Total RNA was isolated from monkey cheek pouch 
vascular tissues [10]. The single-stranded cDNA was synthesized 
from 1 ug of the total RNA using a cDNA synthesis kit (Gibco 
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ttgctcaggcagcctctctgggaag 2 5 
MetLeuLeuLeuProLeuProLeuLeuLeuPhePheLeuCysSerArgAlaGluAlaGly[-2] 
atgctgcttcttcctctccccctgctgctcttttttttgtgctccagagctgaagctggg 85 
GluIleIleGlyGlyThrGluCysLysProHisSerArgProTyrMetAlaTyrLeuGIu[191 
gagatcatcgggggcacagaatgcaagccacactcccgcccctacatggcctacctggaa 14 5 
IleValThrSerAsnGlyProSerLysSerCysGlyGlyPheLeuIleArgArgAsnPhe[40] 
attgtcacctccaacggtccctcaaaatcttgtggtggtttcctgataagacggaacttt 205 
ValLeuThrAlaValHisCysAlaGlyArgSerIleThrValThrLeuGlyAlaHisAsn[59] 
gtgctgacagccgttcattgtgcaggaaggtctataacagtcacccttggagcccataac 2 65 
IleThrGluLysGluAspThrTrpGlnLysLeuGluValIleLysGlnPheArgHisPro[79] 
ataacagagaaagaagacacatggcagaagcttgaggttataaagcaattccgtcatcca 325 
LysTyrAsnThrSerThrLeuHisHisAspIleMetLeuLeuLysLeuLysGluLysAla[99] 
aaatataacacttctactcttcaccacgatatcatgttactaaagttgaaggagaaagcc 3 85 
SerLeuThrLeuAlaValGlyThrLeuProPheProSerGlnPheAsnPheValProPro[119] 
agcctgaccctggctgtggggacactccccttcccatcacaattcaactttgtcccacct 445 
GlyArgMetCysArgValAlaGlyTrpGlyArgThrGlyValLeuLysProGlySerAsp[13 9] 
gggagaatgtgccgggtggctggctggggaagaacaggtgtgttgaagccgggctcagac 505 
ThrLeuGlnGluValLysLeuArgLeuMetAspProGlnAlaCysSerHisPheArgTyr[159] 
actctgcaagaggtgaagctgagactcatggatccccaggcctgcagccacttcagatac 5 65 
PheAspHisAsnLeuGlnLeuCysValGlyAsnProArgLysThrLysSerAlaPheLys[179] 
tttgaccacaatcttcagccgtgtgtgggcaatcccaggaagacaaaatctgcatctaag 625 
GlyAspSerGlyGlyProLeuLeuCysAlaGlyValAlaGlnGlyIleValSerTyrGly[199] 
ggagactctgggggcccccttctgtgtgctggggtggcccagggcattgtatcctatgga 685 
ArgLeuAspAlaLysProProAlaValPheThrArgIleSerHisTyrArgProTrpIle[219] 
cggttggatgcaaagccccctgctgtctccacccgaatctcccattaccggccctggatc 745 
AsnLysIleLeuGlnAlaAsn*** [226] 
aacaagatcctgcaggcaaattaaccctggatcctgagccagcctgaa 793 
Fig. 1. Nucleotide sequence and deduced amino-acid sequence of monkey chymase. The deduced encoded amino acids are indicated below the 
corresponding nucleotides. The amino-terminal sequence determined with the purified monkey chymase is underlined. The nucleotide sequence 
data is available from DDJB/EMBL/GenBank with accession No. AB000823. 
BRL, Gaithersburg, MD). PCR primers for amplification of monkey 
chymase were designed based on the 5' untranslated region and the 
3' untranslated region of human chymase cDNA [11], (sense strand: 
5'-TTGCTCAGGCAGCCTCTCTG-3', position 234-253; anti-
sense strand: 5'-TTCAGGCTGGCTCAGGATCC-3', position 2994-
2975). Two \A of the reverse transcriptase reaction mixture were added 
to 98 JJ.1 of the PCR buffer containing 25 pmol each of the upstream 
and downstream primers, 100 (J.M dNTPs, 10 mM Tris-HCl (pH 8.3), 
50 mM KC1, 1.5 mM MgCl2 and 2.5 U of Taq polymerase (Boeh-
ringer Mannheim GmbH, Mannheim, Germany). The amplification 
profile was run for 40 cycles: 1 min at 94°C, 1 min at 63°C, and 1 min 
at 72°C. A single 793 bp product was subcloned into a pBS II KS 
vector, and subjected to nucleotide sequencing. For the determination 
of the accurate sequence, we used the five PCR products amplified 
independently. 
2.5. Quantitative reverse transcription (RT)-PCR analysis 
Total RNA was isolated from the thoracic aorta as described pre-
viously [10]. Single-stranded cDNA was synthesized from 4 |xg of the 
total RNA. A competitive RT-PCR reaction was performed using a 
modified procedure of Shiota et al. [12]. The PCR primers were se-
lected according to the monkey chymase cDNA sequence (sense pri-
mer: 5'-GGAAGATGCTGCTTCTTCCTC-3', position 21-41; anti-
sense primer: 5'-TTTGTCTTCCTGGGATTGCC-3', position 612-
593). The competitor DNA was obtained by deleting the 201-bp frag-
ment using the restriction enzymes StuI and EcoRV. The PCR prod-
ucts for the target monkey chymase and the competitor were 592 and 
391 bp, respectively. 
2.6. Histological analysis 
The area of the atherosclerotic lesion of the thoracic aorta was 
measured as described previously [13]. The thoracic aortas were 
stained with oil red O for visualization of the presence of lipid depos-
Table 1 
Purification of chymase from monkey cheek pouch vascular tissues 
Purification step Total protein (mg) Chymase activity (mU) Specific chymase activity (mU/mg protein) Recovery (%) 
1. Membrane extract 
2. Filtration on PM-10 
3. Heparin affinity column 
4. Gel filtration column 
1825 
1386 
2.120 
0.240 
6000 
5124 
3794 
1042 
3.29 
36.97 
1789.6 
4340.8 
100 
85.4 
63.2 
17.4 
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Monkey 
Human 
Dog 
RMCP I 
RMCP II 
1 10 20 30 40 50 60 
IIGGTECKPHSRPYMAYLEIVTSNGPSKSCGGPLIRRNFVLTAAHCAGRSITVTLGAHNI 
S---
-V-SR--
-V-SI--
-H L-LRNHLA--
-H T-ER-YKAT-
-H-D EK-LRVI-
-VT-Q-
--S-Q-
F-M 
-K--ET 
-K--E 1-
-V-DV 
---DV 
Monkey 
Human 
Dog 
RMCP I 
RMCP II 
70 80 90 100 110 120 
TEKEDTWQKLEVIKQFRHPKYNTSTLHHDIMLLKLKEKASLTLAVGTLPFPSQFNFVPPG 
DDL--R-
■-N--FYSNL-
-ES--SVPNL-
QKE 
SKT-S-Q-
RKR-STQ-
-IK-E-
■IK-E-
N 
QK--KV-P-
EK-VE--P-
LSP 
-DVI-L-QPSD-LK--
- N W - L - - P S D - I H - -
130 140 150 160 170 180 
Monkey RMCRVAGWGRTGVLKPGSDTLQEVKLRLMDPQACSHFRYFDHNLQLCVGNPRKTKSAFKG 
Human D 
Dog KRQ-NGS R-YMA 
RMCP I K A Q T--T-N--R Q-I--KE--KNYFHYNY-FQV S IR--Y--
RMCP II A--WA K RD-T-Y--R--E--I--EK--VDY--YEYKF-V S-TTLRA--M-
190 200 210 220 
Monkey DSGGPLLCAGVAQGIVSYGRLDAKPPAVFTRISHYRPWINKILQAN 
Human S Q 
Dog QN V-KQ-KA 
RMCP I V H G P-V VIKGKD 
RMCP II H HP I V-T-V AVINTSS 
Fig. 2. Comparison of deduced amino-acid sequence of between monkey chymase with those of other chymases. The deduced amino-acid se-
quence of monkey chymase compared with those of human chymase [16,17], dog chymase [25], RMCP I [26] and RMCP II [20]. 
its. The atheromatic area was calculated as the ratio of the oil-red 
stained area to all of the intima area. 
3. Results and discussion 
The membrane extract of monkey cheek pouch vascular 
tissues on a heparin affinity column yielded a single peak at 
1.6 M KC1. After the active fractions were concentrated and 
applied on a gel filtration column, a 1319-fold purification 
was achieved with a recovery rate of 17.4% and a specific 
activity of 4341 mU/mg (Table 1). The purified enzyme has 
a single band at 30 kDa on SDS-PAGE. The optimum pH of 
the Ang II-forming activity of the purified enzyme was be-
tween 7.5 and 8.5. The enzyme activity was inhibited by 10 
uM SBTI, 1 mM PMSF and 100 uM chymostatin, but not by 
1 mM EDTA, 1 mM phosphoramidon, 1 mM pepstatin, 10 
mM captopril, 10 mM lisinopril and 1 mM aprotinin; there-
fore, the possibility that this activity was cathepsin G [14] or 
tonin [15] was ruled out. The sequence of the first 24 amino 
acids of the purified enzyme exhibited a high homology to 
that of human chymase (100%), dog chymase (78%), rat chy-
mases (RMCP I, 71%; RMCP II, 71%), and hamster chymase 
(78%>). We identified this Ang II-forming protease as monkey 
chymase. 
Chymase is a chymotrypsin-like endopeptidase that hydro-
lyzes the carboxy-terminal side of aromatic amino acids such 
as Phe, Tyr, and Trp. Chymases isolated from human 
[3,16,17], dog [18,19] and rat [20-22] show similar substrate-
binding profiles when 4-nitroanilide substrates are used [23]; 
however, they behave differently when hormonal peptides are 
used. RMCP I [4,5] and dog chymase [24] hydrolyze the Phe7-
Phe8 bond of substance P and the Tyr22-Leu23 bond of vaso-
active intestinal peptide (VIP), and RMCP I [4,5] cleaves the 
Tyr4-Ile5 bond of Ang II, while human chymase hydrolyzes 
none of these bonds [3]. The monkey chymase isolated in this 
study rapidly converted Ang I to Ang II (Km = 98 uM, 
I^ max = 2.48 nmol/min, fccat = 6203/min) but did not degrade 
several peptide hormones including substance P, VIP, and 
Ang II (Table 2). These results indicate that primate chymases 
may have a higher substrate specificity than non-primate chy-
mases. 
The sequence of 247 amino acids deduced from the cDNA 
open reading frame includes peptides identical to the amino-
terminal sequence of the purified monkey chymase (Fig. 1). 
The first 19 residues of monkey prepro chymase represent the 
hydrophobic signal peptide, and the next prosequence of 
2 amino acids is removed to give a mature enzyme of 226 
amino acids. Based on the number of basic (Arg+Lys = 29) 
Table 2 
Comparison of substrate speciflties of monkey chymase with human chymase and RMCP I 
Peptide substrates 
Ang I 
Ang II 
Bradykinin 
LH-RH 
Met-Enkephalin 
ce-MSH 
Somatostatin 
Substance P 
VIP 
Monkey chymase 
C 
N 
N 
T 
N 
T 
N 
N 
N 
Human chymase 
C 
N 
N 
N 
T 
N 
T 
N 
RMCP I 
C 
C 
N 
C 
C 
c 
C, complete, T, trace, N, none. 
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Fig. 3. (A) The atherosclerotic area of the thoracic aorta of monkeys fed a normal or a high-cholesterol diet. (B) The aortic chymase mRNA 
levels of monkeys fed a normal or a high-cholesterol diet. Vertical bars represent S.E.M. **P<0.01 vs. respective monkeys fed a normal diet. 
and acidic (Asp+Glu= 14) amino acids, the monkey chymase 
catalytic domain has a predicted net charge of +15 (Fig. 1), 
and that of human chymase [16,17], dog chymase [25] and 
RMCP I [26] are +13, +16 and +18, respectively. Despite 
the differences in net charges, chymases are reported to bind 
to heparin glycosaminoglycan [27-29]; therefore, it is reason-
able to assume that monkey chymase will bind in the same 
manner. Like human chymase, monkey chymase has two con-
sensus N-linked glycosylation sites (Asn-X-Ser/Thr) at Asn59 
and Asn82 (Fig. 1). Dog chymase also has two sites, but at 
Asn100 and Asn134 [25], and no such sites are found in RMCP 
I [26] and RMCP II [20]. The predicted N-linked glycosylation 
sites in monkey chymase, as deduced from the crystallography 
of RMCP II [22], are some distance away from the active-site 
binding cleft, which coincides with our observation that the 
substrate specificity of the native monkey chymase for hormo-
nal peptides did not change after deglycosylation (unpublished 
data). The deduced primary structure of monkey chymase is 
more homologous to that of human chymase (98%) than dog 
chymase (84%) and rat chymases (RMCP I, 61%; RMCP II, 
59%) (Fig. 2). 
In the present study, we further investigated the patho-
physiological role of vascular chymase in the atherosclerotic 
aorta. After loading with a high-cholesterol diet for 6 months, 
remarkable atherosclerotic degeneration was observed in the 
thoracic aorta and the chymase mRNA levels of monkeys fed 
the atherogenic diet were triple the levels of monkeys fed the 
normal diet (Fig. 3). Recently, we reported that an Ang II 
receptor antagonist significantly prevented the formation of 
atherosclerotic lesions in monkeys fed a high-cholesterol diet 
[30]. Chymase is considered to be derived from mast cells 
[31,32]. Kaartinen et al. demonstrated that the number of 
activated mast cells was increased in human atherosclerotic 
lesions [33]. These findings suggest that the chymase-depend-
ent Ang II-forming pathway may be related to the pathogen-
esis of atherosclerosis. 
In conclusion, the primary structure of monkey chymase is 
highly homologous to human chymase and has a higher spe-
cificity of Ang II-formation than do non-primate chymases. 
In the present study, we first demonstrated that vascu-
lar chymase mRNA is remarkably increased in the mon-
key aorta concurrently with the development of atheroscle-
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